| NCT03632798 | III | Recurrent ovarian cancer | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MS, WV | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03940196 | III | Recurrent ovarian cancer, excluding primary platinum refractory | ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer | AZ, CA, CO, FL, GA, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WA | View Drugs | View Results |
Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | TTfields | NovoTTF-100L(O) | Microtubule destabilizer/mitotic inhibitor | Clinical Trials |
|
|
| NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | CA, FL, LA, TX | View Drugs | View Results |
Anlotinib | Catequentinib, AL3818 | VEGFR2/3 kinase inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT03651271 | II | Recurrent ovarian cancer with dMMR, high MSI or high TMB | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | CA, MA, NY, TX | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A (except clear cell) or ATM alterations | Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03462342 | II | Recurrent ovarian cancer (excluding primary platinum refractory) | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer | MD, MA, PA | View Drugs | View Results |
Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | CA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | CA, FL, MD, MI, MO, NY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03579316 | II | Recurrent ovarian cancer with progression on or after prior PARP inhibitor | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04083976 | II | Advanced solid tumors with FGFR mutations or gene fusions | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | AZ, CO, DE, FL, GA, ME, MA, MI, NJ, NY, NC, OH, PA, TN, TX, WA, WI | View Drugs | View Results |
Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04149275 | II | Recurrent carcinosarcoma | A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | AL | View Drugs | View Results |
Cabozantinib | BMS-907351, Cabometyx, XL184, Cometriq | Multi-targeted RTK inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04171700 | II | Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D, no prior PARP inhibitor | A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes | CA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, TX, WA | View Drugs | View Results |
|
|
| NCT02710253 | II | Advanced solid tumors (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03449108 | II | Recurrent high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
Aldesleukin | Proleukin | IL-2 receptor agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | LN-145-S1 | Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | RG7666, PI3K inhibitor GDC-0084, GDC-0084 | PI3K/mTOR inhibitor | |
|
|
| NCT04003623 | II | Advanced solid tumors with FGFR mutations or translocations | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208) | CA, FL, HI, IL, MD, NJ, OH, SD, TX, UT | View Drugs | View Results |
Pemigatinib | FGFR inhibitor INCB054828, INCB054828, Pemazyre | FGFR1-3 inhibitor | Approved in Other Cancers |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03673124 | II | Recurrent low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | CA, FL, GA, IL, IN, MN, NH, NJ, NM, OH, OK, PA, RI, TX | View Drugs | View Results |
Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response | Clinical Trials |
|
|
| NCT03797326 | II | Advanced solid tumors (in ovarian expansion) | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) | CA, FL, NJ, NY, TN, WI | View Drugs | View Results |
Lenvatinib | E7080, ER-203492-00, Lenvima, MK-7902 | VEGFR1-3 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03868423 | II | Advanced solid tumors with ALK or ROS1 activating genomic aberrations | Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes | OH | View Drugs | View Results |
Brigatinib | AP26113, Alunbrig | ALK and EGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03697304 | II | Advanced solid tumors with prior anti-PD-1/PD-L1 Ab | An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy | CA, FL, IN, KY, OK, TN, WI | View Drugs | View Results |
BI 754091 | anti-PD-1 monoclonal antibody BI 754091 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials | BI 754111 | | Blocks LAG-3 inhibition of T cells | Clinical Trials |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | MA | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT02819843 | II | Advanced solid tumors - intratumoral injection | A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | NJ, NY | View Drugs | View Results |
Radiation Therapy | Radiotherapy, Irradiation | | | Talimogene Laherparepvec | GM-CSF-encoding oncolytic herpes simplex virus, T-VEC | Induces immune response and tumor cell lysis | Approved in Other Cancers |
|
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | NJ, NY | View Drugs | View Results |
Onapristone ER | extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes | |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04383210 | II | Advanced solid tumors with a NRG1 gene fusion | CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors | AZ, CA, CO, FL, IL, MA, MI, MO, NY, NC, TN, TX, VA, WA, WI | View Drugs | |
Seribantumab | SAR256212, MM-121 | ERBB3 antagonist | Clinical Trials |
|
|
| NCT04393454 | II | Advanced solid tumors with dMMR, after prior immunotherapy | Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | NY | View Drugs | View Results |
Sirolimus | Rapamycin, Rapamune | mTOR inhibitor | Approved in Other Indications |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04482309 | II | Advanced HER2+ solid tumors | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | CA, IL, IN, MA, MI, NY, NC, TX, VA, WA | View Drugs | |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT04504942 | II | Advanced CCR5+ solid tumors - subcutaneous injection of leronlimab with standard-of-care chemotherapy | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | CA | View Drugs | View Results |
Leronlimab | anti-CCR5 monoclonal antibody PRO 140 | Modulates the tumor microenvironment and blocks tumor angiogenesis | Clinical Trials |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | LY3214996 | | ERK inhibitor | Clinical Trials |
|
|
| NCT04564027 | II | Advanced solid tumors with ATM mutations | A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) | CA, FL, IN, MD, MA, MI, NV, NY, PA, SC | View Drugs | View Results |
Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | TX | View Drugs | View Results |
Nemvaleukin Alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04239014 | II | Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy | A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment | AK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA | View Drugs | View Results |
Ceralasertib | AZD6738, ATR kinase inhibitor AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, CA, CO, DE, FL, GA, IN, ME, MI, MN, MO, NV, NH, NJ, NM, NY, NC, OH, OR, PA, SC, TN, TX, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | GDC-0077 | RG6114 | PI3K alpha inhibitor | Clinical Trials | Idasanutlin | MDM2 antagonist RO5503781, RG7388, RO5503781 | MDM2 antagonist | | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer with a KRAS mutation | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, MN, OR, TX | View Drugs | View Results |
Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials | VS-6766 | CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766 | RAF and MEK inhibitor | Clinical Trials |
|
|
| NCT04692662 | II | Advanced solid tumors with alterations in ATM, BACH1 (BRIP1), BARD1, BRCA 1/2, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior Pt-regimen; gBRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | MD | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04632992 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, ROS1 or with high TMB or high MSI | MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | AZ, CA, CT, MI, MT, NE, NJ, NY, OH, OR, TN, WA | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | GDC-0077 | RG6114 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04669002 | II | Primary platinum resistant high grade ovarian cancer with no prior PARP inhibitor or recurrent high grade ovarian cancer with at least 2 prior therapies and with prior PARP inhibitor maintenance; no prior bevacizumab | Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease & Are PARP Inhibitor naïve; Cohort 2 - Had at Least 2 Prior Lines of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance | NY, TN, VA | View Drugs | View Results |
EP0057 | IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207 | Topoisomerase I inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04042116 | Ib/II | Primary platinum resistant ovarian cancer (at least 2 prior therapies) or recurrent clear cell ovarian cancer (at least 1 prior therapy), no prior VEGFR tyrosine kinase inhibitor | LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor | CA, CO, FL, MA, NY, NC, OH, OK, PA, TN, WA | View Drugs | View Results |
Lucitanib | VEGFR/FGFR dual kinase inhibitor E-3810 | VEGFR and FGFR kinase inhibitor | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03717415 | Ib/II | Platinum sensitive ovarian cancer | An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | CA, IL, IN, KS, NC, OH, TN, TX | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Rebastinib | multitargeted tyrosine kinase inhibitor DCC-2036 | Multi-targeted RTK inhibitor | Clinical Trials |
|
|
| NCT03872947 | Ib | Platinum sensitive or partially sensitive ovarian cancer with no prior gemcitabine | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, WI | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT03695380 | Ib | Platinum sensitive BRCA WT ovarian cancer with ≤ 2 prior platinum therapies (in expansion) | A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer | AZ, CA, FL, GA, MD, MO, NY, OK, TN, WI | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03206177 | Ib | Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma | Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary | OK | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Galunisertib | LY2157299 | TGFBR1 antagonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03318445 | Ib | Advanced solid tumors with BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51B/C/D/L mutations (in expansion) | Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | CA | View Drugs | |
Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02650986 | I/IIa | Advanced NY-ESO-1+ solid tumors | A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies | NY | View Drugs | |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Decitabine | dezocitidine, deoxyazacytidine, 5-aza-dCyd, Dacogen | DNA methylation inhibitor | Approved in Other Cancers | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | Clinical Trials | TGFbeta DNRII-transduced Autologous Tumor Infiltrating Lymphocytes | TGFbeta Dominant Negative Receptor II transduced TILS | TGFbeta ligand trap, Anti-tumor immune response enhanced by TGFbeta inhibition | Clinical Trials |
|
|
| NCT03110107 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | GA, MA, NJ, NY, PA, SD | View Drugs | View Results |
BMS-986218 | | Blocks CTLA-4 inhibition of T cells | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03593226 | I/IIa | Advanced solid tumors (in expansion) - intratumoral injection | A Phase I/IIA, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours | CA, NJ, OR | View Drugs | |
AGI-134 | αGal immunotherapy | Anti-tumor immune response | |
|
|
| NCT04021043 | I/II | Advanced solid tumors | Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies | TX | View Drugs | View Results |
BMS-986156 | | GITR (glucocorticoid-induced TNFR) agonist | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT04122625 | I/II | Platinum resistant or refractory ovarian cancer with dMMR, high MSI, BRCA MUT or other DDR alterations, or HRD+, with progressive disease during or after prior anti-PD-1/PD-L1 checkpoint inhibitor | A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment | FL, IL, MA, MI, MO, NY, OH, PA, TX, WA | View Drugs | View Results |
Debio 1143 | IAP inhibitor AT-406, AT-406 | SMAC mimetic and IAP antagonist | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03861793 | I/II | Advanced solid tumors (in ovarian expansion) - subcutaneous injection | A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001) | CA, DC, GA, MI, NY, NC, OH, PA, SC, TX | View Drugs | View Results |
Nemvaleukin Alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03761914 | I/II | Recurrent or persistent WT1+ ovarian cancer | A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers | CA, CO, FL, NJ, NY, OH, TX, VA | View Drugs | View Results |
Galinpepimut-S | SLS 001, WT-1 analog peptide vaccine SLS-001 | Immune response against cancer expressing WT1 | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03767348 | I/II | Advanced solid tumor with high MSI or dMMR - intratumoral injection | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AL, AZ, CA, FL, IA, KY, NY, OR, TN, UT, WA, WI | View Drugs | View Results |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Selpercatinib | LOXO-292, RET kinase inhibitor LOXO-292, Retevmo | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02953457 | I/II | Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or dMMR, HRR gene alterations or LOH high score | A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation | NY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | AZD2171, Cediranib maleate, Recentin | VEGFR1-3 kinase inhibitor | Clinical Trials | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02487095 | I/II | Extrapulmonary small cell ovarian cancer | A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers | MD | View Drugs | View Results |
Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03037385 | I/II | Advanced solid tumors with a RET alteration | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | AZ, CA, CO, DC, FL, MD, MA, MI, MN, MO, NY, OR, PA, TX, WA | View Drugs | |
Pralsetinib | BLU-667 | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03093116 | I/II | Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, OH, PA, TX, VA, WA | View Drugs | View Results |
Repotrectinib | ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005 | ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor | Clinical Trials |
|
|
| NCT02503423 | I/II | Advanced solid tumors with oncogenic activation of the NF-κB pathway or amplification of c-IAP1 or c-IAP2 | Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | AL, CA, CT, GA, IL, MD, MA, NH, NY, NC, OH, OK, OR, PA, TN, TX, WA | View Drugs | View Results |
Tolinapant | XIAP/cIAP1 antagonist ASTX660, ASTX660 | IAP antagonist | Clinical Trials |
|
|
| NCT03175224 | I/II | Advanced solid tumors with MET AMP or MET gene fusions | Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | AZ, CA, DE, FL, LA, MD, MA, MN, MO, NC, OH, PA, SC, TN, UT, WA, WV, WI | View Drugs | View Results |
Bozitinib | CBT-101, APL-101 | c-Met kinase inhibitor | Clinical Trials |
|
|
| NCT04590326 | I/II | Recurrent ovarian cancer | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) | Contact research study staff | View Drugs | |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | REGN4018 | anti-MUC16/CD3 bispecific antibody REGN4018 | Re-directs T cells to attack MUC16 (CA125)+ tumor cells | Clinical Trials | REGN5668 | | Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells | Clinical Trials |
|
|
| NCT04315233 | I | Recurrent serous ovarian cancer | A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE) | UT | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04329494 | I | Recurrent ovarian cancer (with peritoneal disease) | Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) | CA | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers |
|
|
| NCT04630769 | I | Recurrent ovarian cancer, excluding primary platinum refractory | Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Contact research study staff | View Drugs | |
Aldesleukin | Proleukin | IL-2 receptor agonist | Approved in Other Cancers | Enoblituzumab | mab MGA271, MGA271 | Immune response against cancer expressing B7H3 | Clinical Trials | FT516 | iPSC-derived non-cleavable CD16 (hnCD16) Fc receptor expressing NK cells FT516 | Anti-tumor immune response | Clinical Trials |
|
|
| NCT04608409 | I | Partially platinum sensitive, platinum resistant or refractory ovarian cancer | A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer | KY | View Drugs | |
Lapatinib | GW2016, GSK572016, lapatinib ditosylate, Tykerb | EGFR and HER2 kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04611139 | I | Small cell of hypercalcemic type (SCCOHT), clear cell, or endometrioid ovarian cancer with SMARCA4 or ARID1A mutations | Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers | AZ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Seclidemstat | LSD1 inhibitor SP-2577, SP-2577 | LSD1 inhibitor | Clinical Trials |
|
|
| NCT04703920 | I | Recurrent high grade serous ovarian cancer | A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | MI | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04707248 | I | Recurrent ovarian cancer (inc expansion) | Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | OK, PA, TN | View Drugs | |
DS-6000a | | ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT04711161 | I | Recurrent ovarian cancer (inc expansion) | Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | TX | View Drugs | |
GRN-300 | | SIK2/3 inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04706962 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer | Contact research study staff | View Drugs | |
TH1902 | | ADC: anti-SORT1 + microtubule stabilizer/mitotic inhibitor (docetaxel) | Clinical Trials |
|
|
| NCT01434316 | I | Advanced solid tumors including those with BRCA1/2 mutations (in expansion) | Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors | MA | View Drugs | View Results |
Dinaciclib | CDK inhibitor SCH 727965, SCH 727965 | CDK1, 2, 5, 9 inhibitor | Clinical Trials | Veliparib | ABT-888 | PARP inhibitor | Clinical Trials |
|
|
| NCT02269293 | I | Advanced ovarian cancer at first recurrence | A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | NJ, NY | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Selinexor | selective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, Xpovio | Selective inhibition of nuclear export (SINE) | Approved in Other Cancers |
|
|
| NCT02498912 | I | MUC16ecto+ recurrent high grade serous ovarian cancer (> 2 prior therapies) | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | NY | View Drugs | View Results |
4H11-28z/fIL-12/EFGRt+ CAR T | 4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes | Immune response against cancer expressing MUC16ecto | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT01376505 | I | Advanced solid tumors (in ovarian expansion) | Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors | OH | View Drugs | View Results |
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine | B-Vaxx | Immune response against cancer expressing HER2 | Clinical Trials |
|
|
| NCT02627443 | I | Platinum sensitive ovarian cancer at first or second recurrence | Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer | AZ, CO, FL, KY, MN, NJ, PA, VA | View Drugs | View Results |
Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01543763 | I | Advanced solid tumors (in ovarian expansion) | Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | CA | View Drugs | View Results |
Abexinostat | HDAC inhibitor CRA-024781, PCI-24781 | HDAC inhibitor | | Pazopanib | Votrient | Multi-targeted RTK inhibitor | |
|
|
| NCT03386526 | I | Advanced solid tumors (in expansion) | A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies | MI, TX | View Drugs | View Results |
APG-1387 | | SMAC mimetic and IAP antagonist | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03059823 | I | Advanced solid tumors (in expansion) | A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors | AZ, MI, NJ, NC, TX, VA | View Drugs | View Results |
Retifanlimab | INCMGA00012, anti-PD-1 monoclonal antibody MGA012, MGA012 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT03502733 | I | Advanced solid tumors (in expansion) | Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilmumab | MD, TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03691376 | I | Recurrent or refractory NY-ESO-1+ ovarian cancer | A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NY | View Drugs | |
Aldesleukin | Proleukin | IL-2 receptor agonist | Approved in Other Cancers | Melphalan | Sarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustard | DNA damaging agent | Approved in Other Cancers | NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials | NY-ESO-1 CD8-TCR Engineered T Cells | | Immune response against cancer expressing NY-ESO-1 | Clinical Trials |
|
|
| NCT03054298 | I | Recurrent or persistent mesothelin+ serous ovarian cancer | Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers | PA | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03585764 | I | Recurrent or persistent FRalpha+ high grade serous ovarian cancer | Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PA | View Drugs | |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | MOv19-BBz CAR T | | Immune response against cancer expressing folate receptor | Clinical Trials |
|
|
| NCT03508570 | I | Recurrent ovarian cancer with disease in the peritoneal cavity or retroperitoneal lymph nodes (in ovarian expansion) | Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers | TX | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03552471 | I | Recurrent FRalpha+ ovarian cancer, excluding platinum-sensitive at first recurrence and primary platinum refractory (in expansion) | Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | OH | View Drugs | View Results |
Mirvetuximab Soravtansine | Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4 | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03748186 | I | Recurrent high grade serous ovarian cancer, excl. primary platinum refractory (in ovarian expansion) | A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers | CO, FL, IL, NV, NC, OH, PA, TN, WI | View Drugs | View Results |
STRO-002 | | ADC: anti-FOLR1 + microtubule destabilizer (SC209) | Clinical Trials |
|
|
| NCT02516813 | I | Ovarian cancer with an indication for palliative radiation therapy | An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors | FL, NY, PA | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT03934814 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | AL, AZ, CA, CT, FL, IN, MI, MN, NY, TN, WA | View Drugs | View Results |
Lemzoparlimab | TJ011133, TJC4 | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04149145 | I | Recurrent ovarian cancer with progression on prior PARP inhibitor (inc expansion) | Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer | AL | View Drugs | View Results |
|
|
| NCT04092270 | I | Recurrent ovarian cancer (inc expansion) | A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) | MA, NJ, NY, OK, VA, WI | View Drugs | View Results |
Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nedisertib | M3814, DNA-PK inhibitor MSC2490484A, Peposertib | DNA-PK inhibitor | Clinical Trials |
|
|
| NCT04182516 | I | Advanced solid tumors (inc ovarian expansion) | A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors | TX | View Drugs | |
NMS-03305293 | | PARP inhibitor | Clinical Trials |
|
|
| NCT03454451 | I | Advanced solid tumors (in expansion) | A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination With Ciforadenant, With Pembrolizumab, and With Ciforadenant Plus Pembrolizumab in Adult Subjects With Advanced Cancers | AZ, CA, CT, FL, IL, MD, MA, NV, NY, NC, OH, OK, PA, SC, TN, TX, VA, WI | View Drugs | View Results |
Ciforadenant | adenosine-A2A receptor antagonist CPI-444, CPI-444 | Blocks adenosine A2A receptor inhibition of T cells | Clinical Trials | CPI-006 | anti-CD73 monoclonal antibody CPI-006, CPX-006 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03968406 | I | Recurrent ovarian cancer (amenable to radiation therapy) - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | TX | View Drugs | View Results |
Radiation Therapy | Radiotherapy, Irradiation | | | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03219268 | I | Advanced solid tumors, including HER2+ cohort (in ovarian expansion) | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms | AZ, CA, FL, IL, MD, MA, NC, OH, OK, PA, TN, TX | View Drugs | View Results |
Margetuximab-cmkb | anti-HER2 monoclonal antibody MGAH22 margetuximab, anti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibody | HER2 antagonist | Approved in Other Cancers | Tebotelimab | MGD013, dual-affinity retargeting protein MGD013, anti-PD-1/anti-LAG-3 DART protein MGD013 | Blocks LAG-3 and PD-1 inhibition of T cells | Clinical Trials |
|
|